New gram-positive agents: The next generation of oxazolidinones and lipoglycopeptides

Matthew P. Crotty, Tamara Krekel, Carey Ann D. Burnham, David J. Ritchie

Research output: Contribution to journalArticle

26 Scopus citations


The growing problem of antimicrobial resistance among bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a critical state. Tedizolid phosphate, dalbavancin, and oritavancin have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and represent the next generation of oxazolidinones and lipoglycopeptides. All three agents exhibit in vitro activity and clinical efficacy against MRSA. Tedizolid phosphate and oritavancin demonstrate in vitro activity against VRE. These new Gram-positive agents are reviewed here.

Original languageEnglish
Pages (from-to)2225-2232
Number of pages8
JournalJournal of clinical microbiology
Issue number9
StatePublished - Sep 2016

Fingerprint Dive into the research topics of 'New gram-positive agents: The next generation of oxazolidinones and lipoglycopeptides'. Together they form a unique fingerprint.

  • Cite this